References
- Fisher B, Slack NH, Bross IDJ. Cancer of the breast: Size of neoplasms and prognosis. Cancer 1969; 24: 1071–1080
- Cooper RG, Holland JF., Glidewell O. Adjuvant chemotherapy of breast cancer. Cancer 1979; 44: 793–798
- Cooper RG. Adjuvant chemotherapy for breast cancer: 20 years experience using CMFVP chemotherapy. Semin Oncol 1988; 15(3)29–34
- Tormey DC, Weinberg VE, Holland JF, et al. A Cancer and Leukemia Group B study. A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer. J Clin Oncol 1983; 1: 138–145
- Hart RD, Perloff M, Holland JF. One-day VATH (vinblastine, adriamycin, thiotepa and halotestin) therapy for advanced breast cancer refractory to chemotherapy. Cancer 1981; 48: 1522–1527
- Perloff M, Norton A, Korzun A, et al. Advantage of an adriamycin combination plus halotestin after initial cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisone for adjuvant therapy for node positive stage II breast cancer. Proc ASCO 1986; 5: 273
- Jones RB, Holland JF, Bhardwaj S, et al. A phase I-II study of intensive dose adriamycin for advanced breast cancer. J Clin Oncol 1987; 5: 172–177
- Fisher B, Redmond C, Fisher ER, et al. Systemic adjuvant therapy in treatment of primary operable breast cancer: National surgical adjuvant breast and bowel project experience. Proceedings of the NIH consensus development conference on adjuvant chemotherapy and endocrine therapy for breast cancer. NCI Monogr 1986; 1: 35–43
- Bonnadonna G. Conceptual and practical advances in the management of breast cancer. J Clin Oncol 1989; 7: 1380–1397
- Buzdar AU, Smith TL, Blumenschein GR, . Adjuvant chemotherapy with fluorouracil, doxorubicin and cyclophosphamide (FAC) for stage II or III breast cancer: 5-year results. Adjuvant Therapy of Cancer III, SE. Salmon, SE. Jones, et al. Grune & Stratton, New York 1981; 419–426
- Hryniuk W, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1986; 4: 1162–1170
- Norton L. Implications of kinetic heterogeneity in clinical oncology. Semin Oncol 1985; 12: 231–249
- Norton L. A gonipertzian model of human breast cancer growth. Cancer Res 1988; 48: 7067–7071
- Coldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63: 1727–1733